| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Address correspondence to Andrew J. Bauer, M.D., Department of Pediatrics, Uniformed Services University, 4301 Jones Bridge Road, Bethesda, MD 20814-4799; tel 202 782 0055; fax 202 782 0740; e-mail abauer{at}usuhs.mil.
Papillary thyroid carcinomas (PTC) are the most common thyroid cancers in children. Most are successfully treated with surgery and radioactive iodine, but some persist. PTC express high levels of vascular endothelial growth factor (VEGF) and VEGF receptor (Flt-1). PTC with the most intense expression of VEGF have the greatest recurrence risk. We hypothesized that blockade of VEGF would inhibit PTC growth. To test this, we used systemic VEGF monoclonal antibody (VEGF-MAb) to treat PTC xenografts in nude mice. Treated animals (n = 9) received 200 µg VEGF-MAb by daily ip injection for 10 wk, while control animals (n = 9) received vehicle alone. Tumor size was significantly reduced in the treatment group (0.28 ± 0.06 vs 1.05 ± 0.25 g, p = 0.008). VEGF immunostaining was more intense (2.57 ± 0.30 vs 1.75 ± 0.25, p = 0.06) and the number of p53 positive cells was increased (1.66 ± 0.24 vs 0.83 ± 0.31, p = 0.048) in treated tumors. Animal weight was similar in both groups (29.1 ± 1.1 vs 27.4 ± 1.1 g, p = 0.30). In conclusion, systemic VEGF-MAb significantly reduced the growth of PTC, suggesting that VEGF-MAb might be useful for treatment of resistant PTC.
Keywords: thyroid cancer, papillary thyroid carcinoma, vascular endothelial growth factor
This article has been cited by other articles:
|
|
 |
|
  J. A Woyach and M. H Shah New therapeutic advances in the management of progressive thyroid cancer Endocr. Relat. Cancer, September 1, 2009; 16(3): 715 - 731. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. E.W. Cohen, L. S. Rosen, E. E. Vokes, M. S. Kies, A. A. Forastiere, F. P. Worden, M. A. Kane, E. Sherman, S. Kim, P. Bycott, et al. Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study J. Clin. Oncol., October 10, 2008; 26(29): 4708 - 4713. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. Pfister and J. A. Fagin Refractory Thyroid Cancer: A Paradigm Shift in Treatment Is Not Far Off J. Clin. Oncol., October 10, 2008; 26(29): 4701 - 4704. [Full Text] [PDF]
|
|
|
|
 |
|
 S.-H. Ahn, Y. Henderson, Y. Kang, C. Chattopadhyay, P. Holton, M. Wang, K. Briggs, and G. L. Clayman An Orthotopic Model of Papillary Thyroid Carcinoma in Athymic Nude Mice Arch Otolaryngol Head Neck Surg, February 1, 2008; 134(2): 190 - 197. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Klubo-Gwiezdzinska, R. Junik, E. Kopczynska, O. Juraniec, and H. Kardymowicz The comparison of serum vascular endothelial growth factor levels between patients with metastatic and non-metastatic thyroid cancer, and patients with nontoxic multinodular goiter Eur. J. Endocrinol., October 1, 2007; 157(4): 521 - 527. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Nahari, R. Satchi-Fainaro, M. Chen, I. Mitchell, L. B. Task, Z. Liu, J. Kihneman, A. B. Carroll, L. S. Terada, and F. E. Nwariaku Tumor cytotoxicity and endothelial Rac inhibition induced by TNP-470 in anaplastic thyroid cancer Mol. Cancer Ther., April 1, 2007; 6(4): 1329 - 1337. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hoffmann, L. C. Hofbauer, V. Scharrenbach, A. Wunderlich, I. Hassan, S. Lingelbach, and A. Zielke Thyrotropin (TSH)-Induced Production of Vascular Endothelial Growth Factor in Thyroid Cancer Cells in Vitro: Evaluation of TSH Signal Transduction and of Angiogenesis-Stimulating Growth Factors J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6139 - 6145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. D. Burman A New Paradigm in the Treatment of Carcinoma: Specific Molecular Targeting Endocrinology, March 1, 2004; 145(3): 1027 - 1030. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
